Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 156

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 156
---
 Plan,   No other matter or circumstance has occurred subsequent to year end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial years. 

F-34

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

18. LOSS PER SHARE
   
                                                                                                                                                    Years Ended June 30,                                  
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                  2025                          2024                           2023                       
Basic and diluted loss per share (cents per share)                                                                                 (0.19   )                      (0.52   )                      (0.57   )
Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share            6,396,924,117                  3,648,875,564                  2,427,841,917    
   The options and warrants in place do not have the effect of diluting the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share. Please refer to Note 11 and Note 16 for options and warrants on issue which were assessed to be antidilutive.

19. KEY MANAGEMENT PERSONNEL COMPENSATION
   
                                                           Years Ended June 30,                        
-------------------------------------------------------------------------------------------------------
                               2025                      2024                       2023               
Short-term employee benefits            1,522,550                  1,551,075                  1,727,020
Post-employment benefits                   18,720                     38,486                     42,444
Long-term benefits                              -                     (6,616   )                  7,215
Termination benefits                            -                     10,215                          -
Share-based payments                      802,128                    520,055                    764,175
                                        2,343,398                  2,113,215                  2,540,854
20. AUDITORS’ REMUNERATION
   
                                                                          Years Ended June 30,                     
-------------------------------------------------------------------------------------------------------------------
                                                 2025                    2024                     2023             
- Audit and review of financial statements (1)            248,000                  248,200                  246,400
- Other audit services (2)                                 72,000                   95,500                   52,000
                                                          320,000                  343,700                  298,400

1.